KRAS Copy Number Gain in Cell-Free DNA Analysis-Based Liquid Biopsy of Plasma and Bile in Patients with Various Pancreatic Neoplasms
International Journal of Molecular Sciences · 2025
DOI: 10.3390/ijms26188763 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2025. Verfasst von Mark Jain und 10 weiteren Autor:innen. Beteiligte Einrichtung: University Clinic, Lomonosov Moscow State University, 119992 Moscow, Russia. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Proto-Oncogene Proteins p21(ras), Bile, Cell-Free Nucleic Acids. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Lomonosov Moscow State University.
Abstract (Originalsprache)
Cell-free DNA (cfDNA) analysis-based liquid biopsy is a rapidly emerging diagnostic and prognostic tool in pancreatic ductal adenocarcinoma (PDAC). KRAS point mutations are the main biomarkers used for the detection of tumor cfDNA. However, there is another less studied yet frequent genetic alteration in this gene, namely copy number gain (CNG). The aim of this study was to evaluate the diagnostic and prognostic potential of KRAS CNG analysis in plasma and bile of patients with PDAC using ddPCR. This study included healthy volunteers (n = 69), patients with PDAC (n = 94), and other pancreatic neoplasms (OPN) (n = 17). The sensitivity and specificity of KRAS CNG compared to the control group were 16% and 100% (AUC-ROC—0.580), and compared to the OPN group, 16% and 94% (AUC-ROC—0.554), respectively. Addition of KRAS point mutations to the analysis increased the sensitivity to 65% (AUC-ROC—0.824 and 0.801, respectively). Bile exhibited an equal KRAS CNG detection rate compared to plasma (20% vs. 16%). KRAS CNG was not associated with clinical parameters, except prognosis. The probability of survival was worse in patients with KRAS CNG (HR—3.54; 95% CI: 1.55–8.12; p = 0.001). KRAS CNG in cfDNA might be a promising biomarker for both diagnostic and prognostic purposes in PDAC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- University Clinic, Lomonosov Moscow State University, 119992 Moscow, Russia.
- Joint Stock Company "Ilyinsky Hospital", 143421 Moscow, Russia.
ORCID-Profile: Mark Jain, Tagir Rakhmatullin, Victoria Inokenteva, Pavel Popov, Mikhail Viborniy, Iuliia Gontareva
Förderung
- Lomonosov Moscow State University
Zitieren
APA
Jain, M., Atayan, D., Rakhmatullin, T., Dakhtler, T., Inokenteva, V., Popov, P., Farmanov, A., Viborniy, M., Gontareva, I., Samokhodskaya, L., & Egorov, V. (2025). KRAS Copy Number Gain in Cell-Free DNA Analysis-Based Liquid Biopsy of Plasma and Bile in Patients with Various Pancreatic Neoplasms. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms26188763
Vancouver
Jain M, Atayan D, Rakhmatullin T, Dakhtler T, Inokenteva V, Popov P, et al. KRAS Copy Number Gain in Cell-Free DNA Analysis-Based Liquid Biopsy of Plasma and Bile in Patients with Various Pancreatic Neoplasms. International Journal of Molecular Sciences. 2025. doi:10.3390/ijms26188763
BibTeX
@article{Jain2025,
author = {Jain, Mark and Atayan, David and Rakhmatullin, Tagir and Dakhtler, Tatiana and Inokenteva, Victoria and Popov, Pavel and Farmanov, Aleksandr and Viborniy, Mikhail and Gontareva, Iuliia and Samokhodskaya, Larisa and Egorov, Vyacheslav},
title = {KRAS Copy Number Gain in Cell-Free DNA Analysis-Based Liquid Biopsy of Plasma and Bile in Patients with Various Pancreatic Neoplasms},
journal = {International Journal of Molecular Sciences},
year = {2025},
doi = {10.3390/ijms26188763}
}
EUVIMED